# FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali

> **NCT00349713** · PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 60 (actual)

## Conditions studied

- Malaria
- Plasmodium Falciparum Malaria

## Interventions

- **BIOLOGICAL:** FMP2.1/AS02A
- **BIOLOGICAL:** Rabies vaccine (RabAvert)

## Key facts

- **NCT ID:** NCT00349713
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-12
- **Final completion:** 2006-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-07-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349713, "FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00349713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*